Cargando…

Hepatitis B virus‐associated follicular lymphoma presents T‐cell inflamed phenotype and response to lenalidomide

Detalles Bibliográficos
Autores principales:	Wang, Nan, Qin, Wei, Zheng, Zhong, Zhao, Ming, Xiong, Jie, Fang, Hai, Sun, Rui, Wang, Yichao, Li, Chen, Dong, Lei, Sun, Xiaojian, Wang, Li, Xu, Pengpeng, Cheng, Shu, Xu, Haimin, Zhang, Fan, Zhao, Weili
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822589/ https://www.ncbi.nlm.nih.gov/pubmed/34854251 http://dx.doi.org/10.1002/cac2.12241

Ejemplares similares

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide
por: Cheng, Lili, et al.
Publicado: (2021)

Advances in the multi-omics landscape of follicular lymphoma
por: Xu, Tianyuan, et al.
Publicado: (2023)

An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date
por: Yilmaz, Umut, et al.
Publicado: (2021)

Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
por: Desai, Madhav, et al.
Publicado: (2013)

Follicular Lymphoma in China: Systematic Evaluation of Follicular Lymphoma Prognostic Models
por: Li, Yanan, et al.
Publicado: (2022)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
por: Li, Ru, et al.
Publicado: (2022)

JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide
por: Xu, Peng-Peng, et al.
Publicado: (2017)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
por: Vitolo, Umberto, et al.
Publicado: (2023)

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
por: Sehn, L. H., et al.
Publicado: (2022)

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Nastoupil, L., et al.
Publicado: (2022)

Genomic and transcriptomic characterization reveals B‐cell hyperactivation and immune evasion in hepatitis B virus‐associated diffuse large B‐cell lymphoma
por: Qin, Wei, et al.
Publicado: (2023)

T Follicular Helper-Like Cells in Inflamed Non-Lymphoid Tissues
por: Hutloff, Andreas
Publicado: (2018)

Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study
por: Zhang, Yan, et al.
Publicado: (2021)

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE
por: Belada, D., et al.
Publicado: (2022)

Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem J. A., et al.
Publicado: (2020)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Integrated Genomic and Transcriptomic Analyses of Diffuse Large B-Cell Lymphoma With Multiple Abnormal Immunologic Markers
por: Sheng, Lingshuang, et al.
Publicado: (2022)

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
por: Morschhauser, Franck, et al.
Publicado: (2021)

Local T/B cooperation in inflamed tissues is supported by T follicular helper-like cells
por: Vu Van, Dana, et al.
Publicado: (2016)

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
por: Sureda, Anna, et al.
Publicado: (2023)

Diagnosis of follicular lymphoma by laparoscopy: A case report
por: Wei, Cheng, et al.
Publicado: (2019)

Lenalidomide in Diffuse Large B-Cell Lymphomas
por: Chiappella, Annalisa, et al.
Publicado: (2012)

Lenalidomide in Diffuse Large B-Cell Lymphoma
por: Thieblemont, Catherine, et al.
Publicado: (2012)

Induced, but not natural, regulatory T cells retain phenotype and function following exposure to inflamed synovial fibroblasts
por: Yang, Sujuan, et al.
Publicado: (2020)

Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma
por: Chiu, Hsiling, et al.
Publicado: (2019)

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
por: Li, Jia, et al.
Publicado: (2021)

Follicular Lymphoma
por: Yavaşoğlu, İrfan
Publicado: (2015)

Follicular lymphoma
por: Leich, Ellen
Publicado: (2019)

The effect of topical application of meloxicam on inflamed dental pulp
por: Li, Jing-Yi, et al.
Publicado: (2021)

Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China
por: Zha, Jie, et al.
Publicado: (2021)

Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma
por: Zhong, Huijuan, et al.
Publicado: (2019)

Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma
por: Zhu, Yue, et al.
Publicado: (2022)

Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma
por: Qin, Wei, et al.
Publicado: (2021)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas
por: Gunnellini, Marco, et al.
Publicado: (2012)

A rare face of follicular lymphoma: reverse variant of follicular lymphoma
por: Maskey, Ninu, et al.
Publicado: (2020)

Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report
por: Zhou, Zhencang, et al.
Publicado: (2022)

Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas
por: Cencini, Emanuele, et al.
Publicado: (2021)

T-cell phenotype including CD57(+) T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma
por: Yang, Zhi-Zhang, et al.
Publicado: (2023)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Mesenteric follicular lymphoma
por: Nishimura, Yoshito, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8oe3orc299jt1isfqv8raphhfe